Spruce Biosciences, Inc. Income Tax Examination, Penalties and Interest Expense
Spruce Biosciences, Inc. (SPRB) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2026-03-09
- Spruce Biosciences, Inc. income tax examination, penalties and interest expense for fiscal 2025 was $0.00.
- Spruce Biosciences, Inc. income tax examination, penalties and interest expense for fiscal 2024 was $0.00.
- Spruce Biosciences, Inc. income tax examination, penalties and interest expense for fiscal 2023 was $0.00.
- Spruce Biosciences, Inc. income tax examination, penalties and interest expense for fiscal 2022 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-09 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-09 |
| 2023-12-31 | $0.00 10-K · filed 2025-04-15 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-18 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-14 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |